Easywell Biomedicals, Inc. (TPEX:1799)

Market Cap	5.58B
Revenue (ttm)	604.93M
Net Income (ttm)	-76.98M
Shares Out	124.69M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,793
Average Volume	152,493
Open	44.60
Previous Close	44.75
Day's Range	44.30 - 45.00
52-Week Range	42.45 - 227.50
Beta	0.12
RSI	42.02
Earnings Date	Aug 12, 2025

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2024, Easywell Biomedicals's revenue was 540.44 million, an increase of 98.96% compared to the previous year's 271.63 million. Losses were -97.47 million, -32.70% less than in 2023.